Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Matrix metalloproteinase-9 (MMP9), and Tumor necrosis factor (TNF-α) (IL1B, IL6, MMP9, TNFA)

This group comprises key mediators of the human inflammatory response, including the cytokines Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α), alongside the enzyme Matrix metalloproteinase-9 (MMP9). IL-1β and TNF-α are primary "alarm" cytokines that initiate the inflammatory cascade, while IL-6 acts as a pleiotropic mediator of the acute phase response and B-cell differentiation (UniProt: P01584, P05231, P01375). MMP9 is a zinc-dependent endopeptidase that degrades type IV collagen in the basement membrane, facilitating leukocyte extravasation and tissue remodeling (UniProt: P14780). Dysregulation of these molecules is central to the pathogenesis of autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease, as well as the "cytokine storm" seen in severe infections (StatPearls: Cytokines, 2023). Therapeutic intervention typically involves monoclonal antibodies (e.g., Adalimumab for TNF-α, Tocilizumab for IL-6) or receptor antagonists (e.g., Anakinra for IL-1β) to mitigate tissue damage and systemic inflammation (PubMed: PMID 31657105). These targets are often measured together as a panel to assess the inflammatory status of a patient or the efficacy of anti-inflammatory therapies.

Other names

Inflammatory mediatorsPro-inflammatory panelCytokine storm markersIL-1 betaIL-6MMP-9TNF-alphaGelatinase B

Monoclonal antibodies or decoy receptors neutralize circulating cytokines to prevent receptor binding and downstream signaling (e.g., NF-κB or JAK/STAT pathways); MMP9 inhibitors target the enzymatic active site to prevent degradation of the extracellular matrix.